Evidence map›Paper›PMID 35840951›Full record

ArticleBMC cancer2022

Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer.

Yoshiya Matsumoto, Tomoya Kawaguchi, Masaru Watanabe, Shun-Ichi Isa, Masahiko Ando, Akihiro Tamiya, Akihito Kubo, Chiyoe Kitagawa, Naoki Yoshimoto, Yasuhiro Koh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Yoshiya MatsumotoDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Tomoya KawaguchiDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Masaru WatanabeInternal Medicine III, Wakayama Medical University, Wakayama, Japan.
Shun-Ichi IsaClinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan.
Masahiko AndoAdvanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
Akihiro TamiyaInternal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan.
Akihito KuboDivision of Respiratory Medicine and Allergology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Chiyoe KitagawaMedical Oncology and Respiratory Medicine, Nagoya Medical Center, Nagoya, Japan.
Naoki YoshimotoRespiratory Medicine, Ishikiriseiki Hospital, Higashiosaka, Japan.
Yasuhiro KohInternal Medicine III, Wakayama Medical University, Wakayama, Japan. ykoh@wakayama-med.ac.jp.
National Kinki Chuo Hospital for Chest Disease · JPWakayama Medical University · JPAichi Medical University · JPIshikiriseiki Hospital · JPNagoya Medical Center · JPNagoya University Hospital · JPOsaka Metropolitan UniversityTokyo Metropolitan University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany previous studies have demonstrated that minor-frequency pretreatment T790M mutation (preT790M) could be detected by ultrasensitive methods in a considerable number of treatment-naïve, epidermal growth factor receptor (EGFR)-mutated, non-small cell lung cancer (NSCLC) cases. However, the impact of preT790M in resected cases on prognosis remains unclear.

methodsWe previously reported that preT790M could be detected in 298 (79.9%) of 373 surgically resected, EGFR-mutated NSCLC patients. Therefore, we investigated the impact of preT790M on recurrence-free survival (RFS) and overall survival (OS) in this cohort by multivariate analysis. All patients were enrolled from July 2012 to December 2013, with follow-up until November 30, 2017.

resultsThe median follow-up time was 48.6 months. Using a cutoff value of the median preT790M allele frequency, the high-preT790M group (n = 151) had significantly shorter RFS (hazard ratio [HR] = 1.51, 95% confidence interval [CI]: 1.01-2.25, P = 0.045) and a tendency for a shorter OS (HR = 1.87, 95% CI: 0.99-3.55, P = 0.055) than the low-preT790M group (n = 222). On multivariate analysis, higher preT790M was independently associated with shorter RFS (high vs low, HR = 1.56, 95% CI: 1.03-2.36, P = 0.035), irrespective of advanced stage, older age, and male sex, and was also associated with shorter OS (high vs low, HR = 2.16, 95% CI: 1.11-4.20, P = 0.024) irrespective of advanced stage, older age, EGFR mutation subtype, and history of adjuvant chemotherapy.

conclusionsMinor-frequency, especially high-abundance of, preT790M was an independent factor associated with a poor prognosis in patients with surgically resected, EGFR-mutated NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsErbB ReceptorsHumansMaleMutationNeoplasm StagingPrognosisProtein Kinase InhibitorsRetrospective StudiesEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsEGFR mutationNon-small cell lung cancerPretreatment T790MRecurrence-free survivalResection

Identifiers

PMID35840951
PMCPMC9288048
OpenAlexW4285490834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.